CTIS2024-515102-12-00进行中（未招募）1 期
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE) - D5339C00001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Capable of giving signed informed consent as described in Appendix B which includes compliance with the requirements and restrictions listed in the ICF and in this protocol., Provision of written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative., Participant must be at least 18 years of age inclusive, at the time of signing the informed consent., Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see Section 5.3.1)., Participant is willing and able to comply with the study protocol for the duration of the study including undergoing treatment and scheduled visits and examinations., Participant must be able to swallow tablets whole.
排除标准
- •Persistent toxicities (> CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy., Pregnant (confirmed with positive pregnancy test) or breast feeding women., Previous allogenic bone marrow transplant., Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection., History of another primary malignancy except for: -Malignancy treated with curative intent and with no known active disease = 2 years before the first dose of study drug and of low potential risk for recurrence -Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease -Adequately treated carcinoma in situ without evidence of disease - Localised non-invasive primary under surveillance, Concurrent severe and/or uncontrolled medical condition (e.g., severe COPD, severe Parkinson’s disease, active inflammatory bowel disease) or psychiatric condition (screening for chronic disease is not required)., Participants with a known hypersensitivity to study interventions or any of the excipients of the products., Major surgery within 2 weeks of starting study intervention: participants must have recovered from any effects of any major surgery., Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)., Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements., Previous enrolment in the present study., Participants with gastrointestinal disorders likely to interfere with absorption of the study intervention.
研究者
相似试验
进行中（未招募）
1 期
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAdvanced Cancer Whose Tumours Contain Molecular AlterationsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2020-002529-27-FRAstraZeneca AB52
进行中（未招募）
1 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very longRelapsed or Refractory B-cell Non-Hodgkin LymphomaMedDRA version: 24.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000870-27-DKAstraZeneca AB272
已完成
2 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very long2024-516386-36-00AstraZeneca AB1
进行中（未招募）
1 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very longRelapsed or Refractory B-cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10076596Term: Marginal zone lymphoma Class: 100000004864MedDRA version: 24.0Level: LLTClassification code: 10067070Term: Follicular B-cell non-Hodgkin´s lymphoma Class: 10029104CTIS2024-516386-36-00AstraZeneca AB12
招募中
1 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very longRelapsed or Refractory B-cell Non-Hodgkin LymphomaMedDRA version: 24.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000870-27-FRAstraZeneca AB272